JP2024532418A - グアンファシン及びモノカルボン酸を含むグアンファシンの経皮投与のための経皮治療システム - Google Patents

グアンファシン及びモノカルボン酸を含むグアンファシンの経皮投与のための経皮治療システム Download PDF

Info

Publication number
JP2024532418A
JP2024532418A JP2024513358A JP2024513358A JP2024532418A JP 2024532418 A JP2024532418 A JP 2024532418A JP 2024513358 A JP2024513358 A JP 2024513358A JP 2024513358 A JP2024513358 A JP 2024513358A JP 2024532418 A JP2024532418 A JP 2024532418A
Authority
JP
Japan
Prior art keywords
guanfacine
containing layer
silicone
weight
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513358A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532418A5 (https=
Inventor
エヴァ－マリー・プリンツ
マルコ・エムゲンブロイフ
パトリック・モーア
シュテファン・ロルシャイト
Original Assignee
エルテーエス ローマン テラピー－ジステーメ アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エルテーエス ローマン テラピー－ジステーメ アーゲー filed Critical エルテーエス ローマン テラピー－ジステーメ アーゲー
Publication of JP2024532418A publication Critical patent/JP2024532418A/ja
Publication of JP2024532418A5 publication Critical patent/JP2024532418A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024513358A 2021-08-30 2022-08-29 グアンファシン及びモノカルボン酸を含むグアンファシンの経皮投与のための経皮治療システム Pending JP2024532418A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21193889 2021-08-30
EP21193889.9 2021-08-30
PCT/EP2022/073922 WO2023031103A1 (en) 2021-08-30 2022-08-29 Transdermal therapeutic system for the transdermal administration of guanfacine comprising guanfacine and a mono-carboxylic acid

Publications (2)

Publication Number Publication Date
JP2024532418A true JP2024532418A (ja) 2024-09-05
JP2024532418A5 JP2024532418A5 (https=) 2024-12-27

Family

ID=77563915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513358A Pending JP2024532418A (ja) 2021-08-30 2022-08-29 グアンファシン及びモノカルボン酸を含むグアンファシンの経皮投与のための経皮治療システム

Country Status (6)

Country Link
US (1) US20240374544A1 (https=)
EP (1) EP4395749B1 (https=)
JP (1) JP2024532418A (https=)
CN (1) CN117897144A (https=)
CA (1) CA3226214A1 (https=)
WO (1) WO2023031103A1 (https=)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07145048A (ja) * 1993-11-25 1995-06-06 Sekisui Chem Co Ltd 医療用貼付剤
JP2012515720A (ja) * 2009-01-20 2012-07-12 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体
WO2017038767A1 (ja) * 2015-08-29 2017-03-09 株式会社メドレックス 経皮吸収組成物
JP2020536882A (ja) * 2017-10-11 2020-12-17 エルテーエス ローマン テラピー−ジステーメ アーゲー 少なくとも１種の添加剤を含むグアンファシンの経皮投与のための経皮治療システム
JP2020536878A (ja) * 2017-10-11 2020-12-17 エルテーエス ローマン テラピー−ジステーメ アーゲー シリコーンアクリルハイブリッドポリマーを含むグアンファシンの経皮投与のための経皮治療システム
JP2021517569A (ja) * 2018-03-13 2021-07-26 エルテーエス ローマン テラピー−ジステーメ アーゲー シリコーンアクリルハイブリッドポリマーを含む、ブプレノルフィンの経皮投与のための経皮治療システム

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101501088B (zh) 2006-06-06 2011-11-30 道康宁公司 有机硅丙烯酸酯混杂组合物
RU2544702C2 (ru) 2009-04-24 2015-03-20 Хенкель Корпорейшн Клеи на основе силикон-акрилового гибридного полимера
JP2013139554A (ja) 2011-11-29 2013-07-18 Dow Corning Corp シリコーンアクリレートハイブリッド組成物及び該組成物の製造方法
WO2016130408A1 (en) 2015-02-09 2016-08-18 Dow Corning Corporation Multi-phase silicone acrylic hybrid visco-elastic compositions and methods of making same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07145048A (ja) * 1993-11-25 1995-06-06 Sekisui Chem Co Ltd 医療用貼付剤
JP2012515720A (ja) * 2009-01-20 2012-07-12 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体
WO2017038767A1 (ja) * 2015-08-29 2017-03-09 株式会社メドレックス 経皮吸収組成物
JP2020536882A (ja) * 2017-10-11 2020-12-17 エルテーエス ローマン テラピー−ジステーメ アーゲー 少なくとも１種の添加剤を含むグアンファシンの経皮投与のための経皮治療システム
JP2020536878A (ja) * 2017-10-11 2020-12-17 エルテーエス ローマン テラピー−ジステーメ アーゲー シリコーンアクリルハイブリッドポリマーを含むグアンファシンの経皮投与のための経皮治療システム
JP2021517569A (ja) * 2018-03-13 2021-07-26 エルテーエス ローマン テラピー−ジステーメ アーゲー シリコーンアクリルハイブリッドポリマーを含む、ブプレノルフィンの経皮投与のための経皮治療システム

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OTA, T. ET AL.: "Evaluating Guanfacine Hydrochloride in the Treatment of Attention Deficit Hyperactivity Disorder (AD", DRUG DESIGN, DEVELOPMENT AND THERAPY, vol. 15, JPN6025041129, 11 May 2021 (2021-05-11), pages 1965 - 1969, ISSN: 0005708220 *

Also Published As

Publication number Publication date
EP4395749C0 (en) 2025-11-19
WO2023031103A1 (en) 2023-03-09
EP4395749A1 (en) 2024-07-10
CA3226214A1 (en) 2023-03-09
CN117897144A (zh) 2024-04-16
US20240374544A1 (en) 2024-11-14
EP4395749B1 (en) 2025-11-19

Similar Documents

Publication Publication Date Title
JP7660162B2 (ja) シリコーンポリマーを含むグアンファシンの経皮投与のための経皮治療システム
JP7659589B2 (ja) シリコーンアクリルハイブリッドポリマーを含むグアンファシンの経皮投与のための経皮治療システム
JP7445218B2 (ja) 少なくとも１種の添加剤を含むグアンファシンの経皮投与のための経皮治療システム
US11389421B2 (en) Transdermal therapeutic system for the transdermal administration of rivastigmine
JP2022540442A (ja) シリコーン含有ポリマーを含む活性剤含有層及びシリコーンゲル接着剤を含む皮膚接触層を含む経皮治療システム
JP2024532418A (ja) グアンファシン及びモノカルボン酸を含むグアンファシンの経皮投与のための経皮治療システム
RU2812734C2 (ru) Трансдермальная терапевтическая система для трансдермального введения гуанфацина, содержащая по меньшей мере одно вспомогательное вещество
RU2792822C2 (ru) Трансдермальная терапевтическая система для трансдермального введения гуанфацина, содержащая силиконовый полимер
JP2020525546A (ja) スコポラミン及びシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
HK40109888B (en) Transdermal therapeutic system for the transdermal administration of guanfacine comprising guanfacine and a mono-carboxylic acid
HK40109888A (en) Transdermal therapeutic system for the transdermal administration of guanfacine comprising guanfacine and a mono-carboxylic acid
HK40034304B (zh) 用於透皮施用胍法辛的包含至少一种添加剂的透皮治疗系统
HK40034304A (en) Transdermal therapeutic system for the transdermal administration of guanfacine comprising at least one additive

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260414